Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Pedro de Alarcon"'
Autor:
Rachel J. Oidtman, Elisa Omodei, Moritz U. G. Kraemer, Carlos A. Castañeda-Orjuela, Erica Cruz-Rivera, Sandra Misnaza-Castrillón, Myriam Patricia Cifuentes, Luz Emilse Rincon, Viviana Cañon, Pedro de Alarcon, Guido España, John H. Huber, Sarah C. Hill, Christopher M. Barker, Michael A. Johansson, Carrie A. Manore, Robert C. Reiner, Jr., Isabel Rodriguez-Barraquer, Amir S. Siraj, Enrique Frias-Martinez, Manuel García-Herranz, T. Alex Perkins
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Newly emerged pathogens are inherently difficult to forecast, due to many unknowns about their biology early in an epidemic. Here, the authors assess forecasts of a suite of models during the Zika epidemic in Colombia, finding that the models that pe
Externí odkaz:
https://doaj.org/article/c817814baca3456fbcbefb36156a6489
Autor:
Amber M. D’Souza, Manu Gnanamony, Maria Thomas, Peter Hanley, Dipti Kanabar, Pedro de Alarcon, Aaron Muth, Nikolai Timchenko
Publikováno v:
Cancers; Volume 14; Issue 13; Pages: 3068
Background: Gankyrin, a member of the 26S proteasome, is an overexpressed oncoprotein in hepatoblastoma (HBL) and hepatocellular carcinoma (HCC). Cjoc42 was the first small molecule inhibitor of Gankyrin developed; however, the IC50 values of >50 μM
Autor:
Amir S. Siraj, Sarah C. Hill, Sandra Misnaza-Castrillón, Erica Cruz-Rivera, John H. Huber, Manuel García-Herranz, Carrie A. Manore, Guido España, Carlos A. Castañeda-Orjuela, Viviana Cañon, Luz Emilse Rincon, Moritz U. G. Kraemer, T. Alex Perkins, Enrique Frias-Martinez, Isabel Rodriguez-Barraquer, Pedro de Alarcon, Michael A. Johansson, Myriam Patricia Cifuentes, Rachel J. Oidtman, Robert Reiner, Elisa Omodei, Christopher M. Barker
Publikováno v:
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature communications, vol 12, iss 1
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
When new pathogens emerge, numerous questions arise about their future spread, some of which can be addressed with probabilistic forecasts. The many uncertainties about the epidemiology of emerging pathogens can make it difficult to choose among mode
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::666a9ef6318fceaf4d5ff90c5c59f9d1
https://doi.org/10.1101/2021.02.25.21252363
https://doi.org/10.1101/2021.02.25.21252363
Neonatal hematology is a fast-growing field, and hematologic problems occur in the majority of sick neonates. Focusing on clinical issues and problem-solving, this is a fully revised and updated revision of a successful practical guide to the pathoge
Autor:
Tanya M, Trippett, Cindy L, Schwartz, R Paul, Guillerman, Alan S, Gamis, Sharon, Gardner, Shirley, Hogan, Wendy B, London, Lu, Chen, Pedro, de Alarcon
Publikováno v:
Pediatric bloodcancer. 62(1)
We assessed the safety and efficacy of ifosfamide and vinorelbine (IV) as a less toxic and effective reinduction regimen for pediatric patients with relapsed or refractory Hodgkin Lymphoma.This multi-center Children's Oncology Group phase II pilot st
Autor:
Pedro de Alarcon, Peter Waldron
Publikováno v:
American Journal of Perinatology. 16:0391-0398
Two siblings born 6 years apart presented with similar findings of hepatosplenomegaly, dermal hematopoiesis, hemoglobinuria, and increased platelet consumption, but only moderate anemia and normal serum bilirubin. ABO incompatibility was identified,
Autor:
Pedro, de Alarcon, Richard, Benjamin, Marion, Dugdale, Craig, Kessler, Rinah, Shopnick, Peter, Smith, Thomas, Abshire, Julie, Hambleton, Prasad, Matthew, Idith, Ortiz, Alice, Cohen, Barbara A, Konkle, Michael, Streiff, Martin, Lee, David, Wages, Laurence, Corash
Publikováno v:
Transfusion. 45(8)
Photochemical treatment (PCT) with amotosalen HCl (S-59) was developed to inactivate pathogens and white blood cells in plasma (PCT-FFP) used for transfusion support.An open-label, multicenter trial was conducted in patients with congenital coagulati
Autor:
Tanya M. Trippett, Cindy L. Schwartz, Richard A. Drachtman, Pedro de Alarcon, Peter D. Cole, Lu Chen
Publikováno v:
Blood. 110:2318-2318
Introduction: This COG Phase 2 study was conducted to assess the efficacy and toxicity of gemcitabine and vinorelbine (GV) in pediatric patients with heavily pre-treated relapsed/refractory Hodgkin disease. Both agents have significant single-agent r
Autor:
Tanya M. Trippett, Richard Sposto, Allen Chen, Sharon Gardner, Pedro de Alarcon, Cindy L. Schwartz, Wendy B. London
Publikováno v:
Blood. 104:2496-2496
A COG Phase II pilot study was conducted to assess the efficacy of the novel re-induction regimen of ifosfamide/vinorelbine (IV) in pediatric patients with heavily pre-treated relapsed/refractory Hodgkin disease. The treatment regimen consisted of :
Publikováno v:
Modern Language Notes. 17:118